These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 18710917)
1. In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme. Li CR; Yang XY; Lou RH; Zhang WX; Wang YM; Yuan M; Li Y; Chen HZ; Hong B; Sun CH; Zhao LX; Li ZR; Jiang JD; You XF Antimicrob Agents Chemother; 2008 Nov; 52(11):3875-82. PubMed ID: 18710917 [TBL] [Abstract][Full Text] [Related]
2. Susceptibility of vertilmicin to modifications by three types of recombinant aminoglycoside-modifying enzymes. Yuan M; Han H; Li CR; Yang XY; Li GQ; Cen S; Kang XX; Si SY; Jiang JD; You XF Antimicrob Agents Chemother; 2011 Aug; 55(8):3950-3. PubMed ID: 21646489 [TBL] [Abstract][Full Text] [Related]
3. In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic. You XF; Li CR; Yang XY; Yuan M; Zhang WX; Lou RH; Wang YM; Li GQ; Chen HZ; Song DQ; Sun CH; Cen S; Yu LY; Zhao LX; Jiang JD Antimicrob Agents Chemother; 2009 Oct; 53(10):4525-8. PubMed ID: 19635958 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of netilmicin, gentamicin, and amikacin. Kantor RJ; Norden CW Antimicrob Agents Chemother; 1977 Jan; 11(1):126-31. PubMed ID: 402104 [TBL] [Abstract][Full Text] [Related]
5. Novel aminoglycoside 2''-phosphotransferase identified in a gram-negative pathogen. Toth M; Frase H; Antunes NT; Vakulenko SB Antimicrob Agents Chemother; 2013 Jan; 57(1):452-7. PubMed ID: 23129050 [TBL] [Abstract][Full Text] [Related]
6. The major aminoglycoside-modifying enzyme AAC(3)-II found in Escherichia coli determines a significant disparity in its resistance to gentamicin and amikacin in China. Xiao Y; Hu Y Microb Drug Resist; 2012 Feb; 18(1):42-6. PubMed ID: 22066787 [TBL] [Abstract][Full Text] [Related]
7. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Almaghrabi R; Clancy CJ; Doi Y; Hao B; Chen L; Shields RK; Press EG; Iovine NM; Townsend BM; Wagener MM; Kreiswirth B; Nguyen MH Antimicrob Agents Chemother; 2014 Aug; 58(8):4443-51. PubMed ID: 24867988 [TBL] [Abstract][Full Text] [Related]
8. Enzymatic modification of aminoglycoside antibiotics in gentamicin-resistant gram-negative bacteria. Kettner M; Navarová J; Lebek G; Krcméry V Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Aug; 257(3):372-82. PubMed ID: 6091367 [TBL] [Abstract][Full Text] [Related]
10. Occurrence of aminoglycoside-modifying-enzyme genes aac(6')-aph(2"), aph(3'), ant(4') and ant(6) in clinical isolates of Enterococcus faecalis resistant to high-level of gentamicin and amikacin. Filipová M; Bujdákova H; Drahovská H; Lisková A; Hanzen J Folia Microbiol (Praha); 2006; 51(1):57-61. PubMed ID: 16821713 [TBL] [Abstract][Full Text] [Related]
11. Identification of aminoglycoside-modifying enzymes by susceptibility testing: epidemiology of methicillin-resistant Staphylococcus aureus in Japan. Ida T; Okamoto R; Shimauchi C; Okubo T; Kuga A; Inoue M J Clin Microbiol; 2001 Sep; 39(9):3115-21. PubMed ID: 11526138 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of dactimicin and other aminoglycosides against bacteria producing aminoglycoside-modifying enzymes. Felmingham D; Jones K Drugs Exp Clin Res; 1989; 15(3):133-6. PubMed ID: 2752913 [TBL] [Abstract][Full Text] [Related]
13. Changes in resistance to aminoglycoside antibiotics of different bacterial strains isolated during the period 1978 to 1983. Netilmicin as alternative therapy. Bovelacci A; Montini G; Ramacciotti PG Chemioterapia; 1985 Dec; 4(6):439-44. PubMed ID: 3830413 [TBL] [Abstract][Full Text] [Related]
14. Trends in the gentamicin and arbekacin susceptibility of methicillin-resistant Staphylococcus aureus and the genes encoding aminoglycoside-modifying enzymes. Barada K; Hanaki H; Ikeda S; Yamaguchi Y; Akama H; Nakae T; Inamatsu T; Sunakawa K J Infect Chemother; 2007 Apr; 13(2):74-8. PubMed ID: 17458673 [TBL] [Abstract][Full Text] [Related]
15. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy. Saavedra S; Vera D; Ramírez-Ronda CH Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877 [TBL] [Abstract][Full Text] [Related]
16. Transposon Tn5281 is the main distributor of the aminoglycoside modifying enzyme gene among isolates of Enterococcus faecalis in Tehran hospitals. Feizabadi MM; Shokrzadeh L; Sayady S; Asadi S Can J Microbiol; 2008 Oct; 54(10):887-90. PubMed ID: 18923558 [TBL] [Abstract][Full Text] [Related]
17. [Estimation of level of aminoglycosides susceptibility of bacterial strains isolated from patients with systemic and general infections]. Kowalska-Krochmal B; Dolna I; Dobosz A; Wrzyszcz E; Gościniak G Med Dosw Mikrobiol; 2008; 60(3):205-14. PubMed ID: 19143174 [TBL] [Abstract][Full Text] [Related]
18. Molecular epidemiology of high-level aminoglycoside-resistant enterococci isolated from patients in a university hospital in southern Italy. Zarrilli R; Tripodi MF; Di Popolo A; Fortunato R; Bagattini M; Crispino M; Florio A; Triassi M; Utili R J Antimicrob Chemother; 2005 Nov; 56(5):827-35. PubMed ID: 16186168 [TBL] [Abstract][Full Text] [Related]
19. Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycin. Thornsberry C; Barry AL; Jones RN; Baker CN; Badal RE; Packer RR Antimicrob Agents Chemother; 1980 Aug; 18(2):338-45. PubMed ID: 7447410 [TBL] [Abstract][Full Text] [Related]
20. [The role of aminoglycoside--modifying enzymes in resistance of Gram-negative rods]. Jakoniuk P; Wieczorek P; Sacha PT; Zalewska M; Leszczyńska K Med Dosw Mikrobiol; 2006; 58(4):363-70. PubMed ID: 17642314 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]